Screening for psoriasis therapeutics
In the IMQ-induced psoriasis model whitepaper, we review:
The Imiquimod-induced psoriasis-like inflammation model is based on a single innate antigenic receptor ligand. Since it requires no adjuvants, it is considered a clean model from an immunological viewpoint, resembling most of the features of human psoriatic lesions. It presents epidermal changes based on keratino- cyte hyperproliferation and altered differentiation, contains the presence of inflammatory cells including T cells, DC, and neutrophils; has a functional role for T cells and contains altered vascularity. Papillomatosis are sometimes observed. It’s dependence on IL-23, the resemblance of most features of human psoriatic lesions and its short duration makes it a convenient, cost-effective model for screening immunologically targeted therapies.
"The mouse imiquimod psoriasis model represents a simple, rapid and cost effective method of inducing psoriasis in mice which avoids the expense of labour-intensive breeding programmes which are required for producing the keratinocyte transgenic mouse lines"